# Ovomucin (Gallus gallus domesticus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ovomucin
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Protein
**Also Known As:** Gallus gallus domesticus ovomucin, Egg white glycoprotein, Hen egg ovomucin, Avian ovomucin, Chicken egg mucin, Ovomucin complex, Alpha-beta ovomucin

## Overview

Ovomucin is a high-molecular-weight sialoglycoprotein derived from egg white that comprises roughly 3.5% of total egg white protein by dry weight. Its primary bioactivity stems from sialic acid residues on its carbohydrate chains, which competitively bind viral hemagglutinins and bacterial adhesins to inhibit pathogen attachment to host cells.

## Health Benefits

• Anti-viral activity through haemagglutination inhibition of influenza and rotavirus (in vitro evidence only)
• Anti-bacterial effects against H. pylori and E. coli O157:H7 via sialic acid-mediated binding (in vitro studies)
• Anti-tumor activity showing cytotoxicity on sarcoma-180 cells and tumor regression in mice (animal studies only)
• [Immune system](/ingredients/condition/immune-support) stimulation through macrophage activation and [cytokine](/ingredients/condition/inflammation) production (in vitro, up to 15.4-fold increase in TNF-α)
• Potential intestinal barrier modulation (theoretical, no direct human evidence)

## Mechanism of Action

Ovomucin inhibits viral entry by presenting sialic acid residues that mimic host cell receptors, competitively blocking influenza hemagglutinin and rotavirus VP8* capsid protein from binding epithelial surfaces. Against bacteria, its sialylated oligosaccharide chains bind fimbrial adhesins on H. pylori and E. coli O157:H7, preventing colonization of gastrointestinal mucosa. Antitumor activity is attributed to beta-ovomucin subunit polysaccharide fractions that induce cytotoxicity in sarcoma-180 cells, potentially via [immune modulation](/ingredients/condition/immune-support) and direct cytostatic effects on rapidly dividing cells.

## Clinical Summary

Evidence for ovomucin's bioactivity derives predominantly from in vitro cell culture models and animal studies, with no robust human randomized controlled trials published to date. In vitro studies demonstrated significant haemagglutination inhibition of influenza A and B strains and rotavirus at microgram-per-milliliter concentrations. Murine sarcoma-180 tumor models showed statistically significant reductions in tumor volume following administration of ovomucin polysaccharide fractions, though exact dosing parameters varied across studies. The current evidence base is preclinical, and extrapolation to human therapeutic outcomes requires significant caution until controlled human trials are conducted.

## Nutritional Profile

Ovomucin is a high-molecular-weight glycoprotein comprising approximately 1.5–3.5% of total egg white protein by dry weight, with molecular weight ranging from 220 kDa to over 8,300 kDa depending on subunit aggregation state. It exists as two subunits: α-ovomucin (~220 kDa, relatively low carbohydrate content ~15%) and β-ovomucin (~720 kDa, heavily glycosylated at ~57% carbohydrate by weight). Protein content of purified ovomucin is approximately 40–85% by dry weight depending on purification method. Carbohydrate composition is dominated by N-acetylgalactosamine, N-acetylglucosamine, galactose, mannose, fucose, and sialic acid (N-acetylneuraminic acid); sialic acid content is notably high at approximately 7–12% of total carbohydrate weight, which is central to its bioactive properties. Sulfate groups are present on β-ovomucin polysaccharide chains (chondroitin sulfate-like moieties), contributing to its strong negative charge and gel-forming viscosity in egg white. Ovomucin contains no significant lipid fraction and negligible micronutrient content as an isolated protein. Bioavailability of intact ovomucin after oral ingestion is considered low due to its large molecular size and resistance to gastrointestinal proteolysis; however, partial enzymatic hydrolysis in the gut releases bioactive sialic acid residues and peptide fragments that may exert local gastrointestinal effects. No significant caloric contribution is derived from typical dietary exposure levels in whole egg white (~0.01–0.05 g per large egg).

## Dosage & Preparation

No clinically studied human dosages exist. In vitro studies used ovomucin hydrolysates at 62.5-500 μg/mL (non-cytotoxic up to 250 μg/mL). Animal studies used β-ovomucin fragments (70-220 kDa) without quantified doses. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Ovomucin is derived from egg white, making it an absolute contraindication for individuals with IgE-mediated egg allergies, as exposure can trigger anaphylaxis. No formal drug interaction studies have been conducted; however, its mucus-mimicking viscosity could theoretically slow gastrointestinal absorption of co-administered oral medications if taken in concentrated supplemental form. Pregnancy and lactation safety has not been evaluated in controlled studies, so use during these periods is not recommended beyond dietary egg consumption. Biotin-avidin interactions are not a concern with ovomucin specifically, unlike the egg white protein avidin, but whole egg white preparations may contain both.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for ovomucin. Evidence is limited to in vitro studies using RAW 264.7 macrophage cells (62.5-500 μg/mL doses) and animal models, primarily investigating anti-viral, anti-bacterial, and anti-tumor properties discovered since the 1940s.

## Historical & Cultural Context

No evidence of historical or traditional medicinal use was identified in any traditional medicine systems. Research on ovomucin's biological activities began in modern times, with anti-viral properties first discovered in 1949.

## Synergistic Combinations

Egg white proteins, lysozyme, lactoferrin, immunoglobulins, [prebiotic](/ingredients/condition/gut-health)s

## Frequently Asked Questions

### What is ovomucin and what foods contain it?

Ovomucin is a fibrous sialoglycoprotein found exclusively in egg white, constituting approximately 3.5% of egg white's dry protein content. It exists as two subunits—alpha-ovomucin (low-carbohydrate, ~220 kDa) and beta-ovomucin (high-carbohydrate, ~400–720 kDa)—and is responsible for the gel-like viscosity of raw egg whites. Dietary egg consumption is the primary source, as ovomucin is not widely available as an isolated commercial supplement.

### Can ovomucin help fight the flu or other viruses?

In vitro studies show ovomucin inhibits influenza A and B hemagglutination by presenting sialic acid decoys that block the virus's hemagglutinin surface protein from binding host respiratory cells. Similar inhibition has been demonstrated against rotavirus VP8* protein at microgram concentrations in cell culture models. However, no human clinical trials have confirmed these antiviral effects in vivo, so ovomucin cannot currently be recommended as an antiviral therapeutic or preventative in humans.

### Does ovomucin have any proven antibacterial effects?

In vitro research demonstrates that ovomucin's sialylated carbohydrate chains competitively inhibit adhesion of H. pylori and E. coli O157:H7 to gastrointestinal epithelial cell lines by binding bacterial fimbrial adhesins. This mechanism is analogous to mucin glycoproteins in natural gastric mucosa that serve as a first-line mucosal defense. These findings are limited to cell culture experiments, and no human intervention studies have confirmed antibacterial efficacy at achievable dietary or supplemental doses.

### Is ovomucin safe for people with egg allergies?

No—ovomucin is a major egg white protein and a known allergen capable of triggering IgE-mediated hypersensitivity reactions in egg-allergic individuals, ranging from urticaria to anaphylaxis. Anyone with a diagnosed egg allergy should completely avoid ovomucin-containing products or isolated ovomucin supplements. Even refined ovomucin preparations retain allergenic epitopes and should not be considered hypoallergenic.

### What is the antitumor mechanism of ovomucin?

The antitumor activity of ovomucin has been investigated primarily in murine sarcoma-180 cell models, where beta-ovomucin polysaccharide fractions demonstrated direct cytotoxicity and inhibited tumor cell proliferation. The proposed mechanism involves immune modulation—potentially enhancing macrophage activation—alongside direct cytostatic interference with rapidly dividing cells, though the precise molecular targets such as specific kinases or receptors have not been fully elucidated. This research remains preclinical and has not been replicated in human oncology trials.

### What does the current clinical research show about ovomucin's effectiveness in humans?

Most evidence for ovomucin comes from in vitro (test tube) and animal studies, with limited human clinical trials to date. While studies demonstrate promising anti-viral, anti-bacterial, and immune-stimulating properties in laboratory and rodent models, these results have not been consistently replicated in controlled human trials. More human research is needed to establish whether ovomucin's benefits observed in animal studies translate to meaningful health outcomes in people.

### Who should avoid ovomucin supplementation, and are there specific health conditions that contraindicate its use?

People with egg allergies should strictly avoid ovomucin, as it is derived from chicken eggs and can trigger allergic reactions ranging from mild to severe. Individuals with autoimmune conditions should consult a healthcare provider before supplementing, since ovomucin stimulates macrophage activation and immune system activity, which could potentially exacerbate certain conditions. Pregnant or nursing women should seek medical guidance before use, as safety data in these populations is limited.

### How does ovomucin's mechanism of immune stimulation through macrophage activation differ from other egg-derived immune supplements?

Ovomucin specifically activates macrophages—immune cells that engulf pathogens and cellular debris—through its unique glycoprotein structure and sialic acid content. Unlike some other egg proteins that may support general immune function, ovomucin's sialic acid-mediated binding to pathogens like H. pylori and E. coli provides a targeted mechanism for recognizing specific bacteria. This dual action of immune cell activation plus direct pathogen recognition distinguishes ovomucin from broader egg-derived immune ingredients.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*